Chimeric Therapeutics
4:15 PM - 4:30 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
Chimeric Therapeutics is a clinical stage cell therapy company with encouraging early clinical data in Glioblastoma with CHM 1101 and in HR-MDS/ AML with CHM 0201.
Chimeric believes that novel cell therapies have the promise to cure cancer, not just delay disease progression. To bring that promise to life for more patients Chimeric’s team of cell therapy experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.
Chimeric’s current portfolio includes best-in-class allogeneic NK cell therapies and first-in-class autologous CAR T cell therapies.
Chimeric believes that novel cell therapies have the promise to cure cancer, not just delay disease progression. To bring that promise to life for more patients Chimeric’s team of cell therapy experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.
Chimeric’s current portfolio includes best-in-class allogeneic NK cell therapies and first-in-class autologous CAR T cell therapies.
Ticker:
CHM
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Ontario
Company HQ Country:
Canada
Year Founded:
Not Provided
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
CHM 1101
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
.png)